Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer by Guldvik, IJ, Braadland, PR, Sivanesan, S, Ramberg, H, Kristensen, G, Tennstedt, P, Røder, A, Schlomm, T, Berge, V, Eri, LM, Lilleby, W, Mills, IG, Taskén, KA

The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells by Braadland, PR, Ramberg, H, Grytli, HH, Urbanucci, A, Nielsen, HK, Guldvik, IJ, Engedal, A, Ketola, K, Wang, W, Svindland, A, Mills, IG, Bjartell, A, Tasken, KA

Identification and validation of leucine-rich α-2-glycoprotein 1 as a noninvasive biomarker for improved precision in prostate cancer risk stratification by Guldvik, IJ, Zuber, V, Braadland, PR, Grytli, HH, Ramberg, H, Lilleby, W, Thiede, B, Zucknick, M, Saatcioglu, F, Gislefoss, R, Kvåle, R, George, A, Grönberg, H, Wiklund, F, Neal, DE, Gnanapragasam, VJ, Taskén, KA, Mills, IG